IGF1R and central nervous system cancer: reported that IGF1R neutralizing antibody may inhibit the intracranial growth of U87MG by targeting the growth of blood vessels.[21] Therefore, clinical administration of BBB‐penetrable IGF1R inhibitor is expected to have multiple anti‐glioma effects, both cell‐autonomously and noncell autonomously.